Accent Microcell
- Market cap
- ₹ 1,425 Cr.
- P/E
- 25x
- P/B
- 5.37x
- 52-week range
- 253 – 731.7
- ROE
- 19%
- ROCE
- 25%
- Dividend yield
- 0.2%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Accent Microcell Limited is a global manufacturer of microcrystalline cellulose. It is engaged in the manufacturing of a pharmaceutical excipients range of products. Its segments include Dahej (SEZ Unit), Pirana, and Unit III. It serves various applications, including pharmaceuticals and nutraceuticals; food, bakery and dairy; cosmeceuticals and personal care; textile, leather, paper, and boards; paints, ceramic, construction and cements; welding electrodes; rubber; filtration, plastics. Its comprehensive product portfolio is designed to meet the diverse needs of the pharmaceutical, nutraceutical, food, cosmetic and other industries. Its range includes binders, fillers, target-drug-delivery, disintegrants, lubricants, coatings, and preservatives. Its products include Micro Crystalline Cellulose, Cellulose Powder, Microcrystalline Cellulose Spheres, Silicified Microcrystalline Cellulose, Cross Carmellose Sodium and Magnesium Stearate. It has a global presence spanning over 75 countries.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Accent Microcell against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)25 against a typical 33.2: cheaper than most peers (1st = cheapest).81st of 220
- Sales growth+38.9% against a typical +15.6% from a year earlier.39th of 197
- Profit growth+93.8% against a typical +18.9% from a year earlier.34th of 160
- Share price, 3 months+30.1% against a typical −2%.20th of 200
- Size₹ 1,425 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).78th of 199
Latest announcements
Exchange filings and their impact on the company.
- Strong H1 with 25% sales growth and 72% profit jump points to ~20% sales and ~35% earnings growth over next 12 months.
Accent Microcell reported unaudited H1 FY27 results for the half year ended September 30, 2026 with revenue of Rs 174.83 cr versus Rs 139.37 cr a year ago and net profit of Rs 31.12 cr versus Rs 18.07 cr. Margins expanded on lower input costs and the company generated Rs 78.28 cr from operations while spending Rs 61.31 cr on new plants. The board also confirmed IPO and rights issue funds are fully deployed with extra capex met from internal accruals, supporting continued capacity expansion at Unit III and the new MCC plant.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | — | Stable | 22 Oct 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 22 Oct 2026 | ▲ Upgrade1 notch | — | Low | CRISIL | ₹ 20.92 Cr. | |
| 27 Feb 2026 | Rating action | Crisil B(Issuer Not Cooperating) | — | CRISIL | ₹ 20.92 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Oct 2026 | Board Meeting Intimation | ACCENT MICROCELL LIMITED has informed the Exchange about Board Meeting to be held on 14-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. |
| 12 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 14 Oct 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 22 Aug 2025 | Board Meeting Intimation | ACCENT MICROCELL LIMITED has informed the Exchange about Board Meeting to be held on 22-Aug-2025 to consider and approve Dividend/Other business. |
| 29 May 2025 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 9 May 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 107 | 139 | 126 | 139 | 139 | 210 | 175 |
| Expenses | 87 | 119 | 107 | 115 | 115 | 177 | 134 |
| Operating Profit | 20 | 20 | 19 | 23 | 24 | 33 | 41 |
| OPM % | 18% | 14% | 15% | 17% | 17% | 16% | 24% |
| Other Income | 1 | 2 | 3 | 3 | 3 | 4 | 3 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 3 | 2 |
| Profit before tax | 17 | 19 | 20 | 24 | 24 | 34 | 41 |
| Tax % | 18% | 17% | 16% | 32% | 25% | 25% | 25% |
| Net Profit | 14 | 16 | 16 | 17 | 18 | 26 | 31 |
| EPS in Rs | 8.01 | 6.7 | 6.86 | 6.92 | 7.53 | 10.75 | 12.97 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 21%
- TTM
- 38%
- 10 Years
- —
- 5 Years
- 54%
- 3 Years
- 53%
- TTM
- 64%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 21%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Accent Microcell | ₹ 620.00 | ₹ 1,425 Cr. | 25x | 5.4x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ghanshyam Arjanbhai Patel
- Chief Financial Officer, Managing Director (Promoter)
- Nitin Jasvantbhai Patel
- Whole-Time Director (Promoter)
- Vasant Vadilal Patel
- Whole-Time Director (Promoter)
- Vinodbhai Manibhai Patel
- Whole-Time Director (Promoter)
- Braham Pal Chhabra
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.